Filter Results:
(233)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (233)
- Research (609)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (233)
- Research (609)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 01 Dec 2016
- News
Cast of Characters
The main characters of F.X. Biasi Jr.’s (PMD 41, 1981) first epic, The Brother-in-Law, were too old to star in an ongoing adventure series. So in Biasi’s later thrillers, the mantle is passed on to a son, Navy SEAL Bruce Tanner—“the classic all-American male hero.” In... View Details
Keywords: April White
- 01 Sep 2004
- News
Bill Dunaway (MBA 1964)
A self-described SOB — son of the boss — Bill Dunaway grew up working in his father’s pharmacy in Marietta, Georgia, a town of 61,000 outside Atlanta. After expanding the business to a chain of 18 drug stores, Dunaway sold the operation... View Details
- 01 Dec 2017
- News
2017 in Health Care: Telemedicine Has Arrived
telemedicine services available next year to employees in states that allow it. We’re going to see a lot more investment in this area, from both established health care companies and startups. What’s next in health care? “More constraints on View Details
- 14 Apr 2014
- News
The Puzzle of Life
capitalize companies that may not make sense for venture funds but do make sense for smart angels who have more patience than most VCs." Among those companies: Rani Therapeutics, an early-stage venture focused on making injectable biological View Details
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
wants to understand the barriers to effecting change on global issues such as health care." Under Ray Gilmartin's leadership, Merck has launched an unprecedented number of new drugs and forged partnerships with the public and nonprofit... View Details
- 01 Jun 2012
- News
The Power of Philanthropy
announced its approval of Kalydeco, a drug produced by Vertex that will immediately help some 1,200 cystic fibrosis patients and is viewed as a breakthrough precursor drug to forthcoming products that will... View Details
- 01 Sep 2011
- News
Alumni Team Up to Fight Cancer
networking among its alumni community. Bowes, founding partner of US Venture Partners, and Giusti, founder of the Multiple Myeloma Research Foundation (MMRF), discussed the need for innovative, results-oriented biomedical research and View Details
- 04 Sep 2019
- News
Accelerating Scientific Discovery
reduce human disease and suffering influences his work as a health care economist and researcher. “I imagine a world where we have treatments, ideally cures, for diseases where right now we have nothing,” he says. “So the big questions that motivate me are, what are... View Details
Keywords: Jennifer Gillespie
- 18 Sep 2014
- News
Room to grow: global expansion in the middle ground
consulting firm Shaldor, documents the specific strategies various companies pursued. As examples, by focusing on a neglected market segment, Netafim became the world leader in drip irrigation technology, while Teva Pharmaceutical created a scalable, acquisition-based... View Details
- 01 Dec 2019
- News
The Race Against Resistance
tide. “If we don’t take steps to slow down or stop drug resistance, we will fall back to a time when simple infections killed people. Can you imagine? That’s a bit of a doomsday perspective, but it’s a call to action.” “We are approaching... View Details
Keywords: Lisa Scanlon Mogolov
- 01 Jun 2018
- News
Floor It
case study with the Multiple Myeloma Research Foundation, GNS Healthcare, the Moffitt Cancer Center’s ORIEN program, and biotech firm Foundation Medicine. Rethinking Drug Trials In an adaptive platform trial, different View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- 24 Sep 2020
- News
The Race for a Vaccine
Pisano says. But vaccines don’t really fit the same business model as high-volume therapeutic drugs; they have an even higher bar for safety and effectiveness, because unlike most other drugs they are administered to healthy populations.... View Details
- 01 Sep 2017
- News
Ink: Miami’s Dark Neon Era, the Language of Success, and Getting Psyched Up
and two other amazing, true stories NEW Hotel Scarface by Roben Farzad “There’s so much unresolved about Miami’s cocaine coming-of-age. I found the address where the Cold War crashed into the war on drugs crashed into the cocaine wars... View Details
- 25 Apr 2014
- News
A revolution in healing
Stéphane Bancel (MBA 2000) is president and CEO of Moderna Therapeutics, which is producing a new drug application that could revolutionize the biotech world. It hinges on messenger RNA, or mRNA, the molecules responsible for transporting... View Details
- 01 Mar 2008
- News
The Last Frontier
state for people with debilitating but nonterminal diseases like his to receive, with a doctor’s assistance, drugs with which they may take their own lives. Explained Gardner, “Why do this? I want to be involved in public life. I was... View Details
- 01 Mar 2010
- News
Noted & Quoted
“Unfortunately, the technology for growing flu viruses to make vaccines is fifty years old — it’s chicken eggs.” — HBS Professor of Management Practice and former Merck CEO Raymond Gilmartin, at a November HBS panel discussion on drug... View Details
- 01 Sep 2008
- News
Mara Aspinall
higher efficacy rate — 80 percent or more. Is 80 percent efficacy unusual for drugs currently on the market? Across all patients and diseases, drug efficacy averages 50 percent, so half the time they bring... View Details
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
biotech companies—as a function of cost, time, and failure modes—tend to risk pivot on one program, one clinical trial, one outcome,” he observes. “Our company is the leader in mining muscle biology for drug discoveries that translate... View Details
Keywords: Deborah Blagg
- 20 Aug 2014
- News
With No Time to Lose
into ALS research, and removed some critical barriers to the development of treatments. “Our focus, from the start, was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed with the disease in 2004, just weeks... View Details
Keywords: Margie Kelley
- 24 Apr 2014
- News
Finding a cure so that others may benefit
call. The foundation wanted to invest in for-profit bioscience companies to spur scientists to find a cure for the disease. O’Donnell is credited with almost singlehandedly raising $250 million in support of this venture philanthropy, which led to the development of... View Details